Navigation Links
Sangamo BioSciences to Acquire Ceregene
Date:8/26/2013

RICHMOND, Calif., Aug. 26, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.  Sangamo will host a teleconference at 8:30 am ET tomorrow, Tuesday, August 27, 2013, to discuss the acquisition and provide a general business overview.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

"Ceregene is a leader in development and manufacturing of AAV-based therapies with significant clinical development experience," said Edward Lanphier, Sangamo's president and CEO.  "Since their inception in 2001, the company has safely treated over 115 subjects in four clinical trials. Sangamo has acquired all of Ceregene's AAV assets including CERE-110, AAV delivery of nerve growth factor (NGF) to the brain for the treatment of Alzheimer's disease.  CERE-110 is being evaluated in a fully enrolled and fully funded Phase 2 clinical trial. In addition to the AAV platform, the assets also include one of the world's largest databases of AAV GMP manufacturing know-how, toxicology data, and safety data from their human clinical trials, which will be an invaluable resource as we advance our ZFP Therapeutics."

Under the terms of the definitive agreement Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, which represents less than 0.2 percent of Sangamo's total shares outstanding.  In addition, Sangamo has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene.  The acquisition is
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
2. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
3. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
4. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
5. Sangamo BioSciences Reports First Quarter 2013 Financial Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
9. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
10. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
11. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Cardica, Inc. (Nasdaq: ... for its fiscal fourth quarter and year ended June 30, ... Cardica,s management will host a conference call at 4:30 p.m. ... update on the company,s business. Conference Call Details ... at 4:30 p.m. Eastern Time via phone, please dial 866-953-6859 ...
(Date:7/23/2014)... 23, 2014  Dompe, a leader in R&D for new ... rhNGF (Recombinant Human Nerve Growth Factor) has been designated as ... (FDA). The candidate drug, developed by the ... for the treatment of neurotrophic keratitis, a degenerative corneal disease ... and is currently without a cure. This is the second ...
(Date:7/23/2014)... 2014  Essentialis announced today the receipt of ... (FPWR) to support clinical study PC025, which is ... diazoxide choline controlled release tablets (DCCR) in obese ... at the University of California, Irvine under the ... "We have found that the support of ...
Breaking Medicine Technology:Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome 2
... May 17 US HIFU, a worldwide leader in the development, ... is pleased to announce that its HIFU treatment for prostate cancer is ... Bermuda joins more than 100 centers in 30-plus countries to ... , , ...
... CareFusion (NYSE: CFN ), a leading, global medical device ... leading innovator in clinically differentiated needleless access connectors and administration sets that ... cash. , , , ... an industry leader in IV infusion devices with its Alaris® System and ...
Cached Medicine Technology:High Intensity Focused Ultrasound (HIFU) Treatment for Prostate Cancer Now Available in Bermuda 2High Intensity Focused Ultrasound (HIFU) Treatment for Prostate Cancer Now Available in Bermuda 3High Intensity Focused Ultrasound (HIFU) Treatment for Prostate Cancer Now Available in Bermuda 4CareFusion Completes Medegen Acquisition 2
(Date:7/23/2014)... Ticket Down is reliable source for ... TX at the Cotton Bowl. The 2014 Guinness International ... United States and Canada beginning on July 24. The tournament ... Liga, Serie A, English Premier League, and Superleague Greece. Among ... Olympiacos, Inter Milan, Liverpool, AS Roma, and Real Madrid. The ...
(Date:7/23/2014)... This report defines and segments the "EHV ... Middle East & Africa, and Americas) - Global Trends ... analysis and forecasts of the global revenue. The global ... $10 billion in 2014 to nearly $14 billion by ... browse 49 Market Tables and 10 Figures Spread Through ...
(Date:7/23/2014)... Absolute PhysioCare and Sports Rehab, a Burnaby orthotics ... orthotics and gait scan analysis that will be focused ... restore normal body balance. This treatment can reduce stress ... In addition, Custom orthotics provides shock absorption, extra cushioning, ... relief and greater comfort while walking, running, or playing ...
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... 2014 Adipic acid is an ... a high-performance plastic, often referred to as engineering ... depending on the monomers employed. Due to the ... and the increasing number of developing countries, the ... share, followed by Europe and North America. Adipic ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Slashes Ticket Prices on all AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Slashes Ticket Prices on all AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4
... By Jenifer Goodwin HealthDay Reporter , ... eight genes in the development of alopecia areata, a ... The genes are already associated with other autoimmune ... that drugs may already be in the pipeline that ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... disease patients who received fetal cell transplants in the ... can prevent the troublesome side effect. The findings ... said. "These findings lend much optimism to new ...
... ... Unveils Military-Inspired Website on July 2nd to Expand Support of US Armed Forces and ... ... in performance apparel, footwear and accessories today announced the July 2nd launch of UA ...
... , WEDNESDAY, June 30 (HealthDay News) -- If you want to ... a new study suggests it might be a good idea to ... a link between exercise in adolescence and fewer cases of senility ... that exercise lowers the risk of dementia. And the research is ...
... (APS) ( www.aps.org ), a leading organization of ... Regulatory Commission (NRC) requesting the agency change its ... proliferation risks associated with smaller, more efficient nuclear ... the secret development of nuclear weapons, including incidents ...
... Researchers have identified a set of "molecular signatures" for ... liver transplant in children that can help identify ... outcomes. The Cincinnati Children,s Hospital Medical Center scientists ... only 14 of 47 infants with biliary atresia could ...
Cached Medicine News:Health News:Genes Tied to Hair Loss Disorder 2Health News:Genes Tied to Hair Loss Disorder 3Health News: Parkinson's Transplant Mystery Solved, Researchers Say 2Health News: Parkinson's Transplant Mystery Solved, Researchers Say 3Health News:Under Armour Launches UA Freedom Initiative in Celebration of Independence Day 2Health News:Under Armour Launches UA Freedom Initiative in Celebration of Independence Day 3Health News:Exercise May Guard Girls Against Dementia in Senior Years 2Health News:APS Physics files petition requesting NRC change licensing rules 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: